Skip to Content

Dacarbazine Dosage

Medically reviewed on October 1, 2018.

Applies to the following strengths: 100 mg; 200 mg; 500 mg

Usual Adult Dose for Malignant Melanoma

2 to 4.5 mg/kg IV once a day for 10 days, repeated every 4 weeks or 250 mg/m² IV once a day for 5 days, repeated every 3 weeks.

Usual Adult Dose for Hodgkin's Disease

150 mg/m² IV once a day for 5 days, repeated every 4 weeks or 375 mg/m² IV once, repeated every 15 days in combination therapy.

Renal Dose Adjustments

Data not available

Liver Dose Adjustments

Data not available

Dose Adjustments

Doses are based on ideal body weight. Doses may depend upon the specific indication for use.


-EXPERIENCED PHYSICIAN: It is recommended that this drug be administered under the supervision of a qualified physician experienced in the use of cancer chemotherapeutic agents. In treatment of each patient, the physician must weigh carefully the possibility of achieving therapeutic benefit against the risk of toxicity.
-BONE MARROW SUPPRESSION: Hemopoietic depression is the most common toxicity with this drug.
-HEPATIC EFFECTS: Hepatic necrosis has been reported.
-CARCINOGENIC/TERATOGENIC: In animal studies, this drug has demonstrated a carcinogenic and teratogenic effect.

Consult WARNINGS section for additional precautions.


Data not available

Other Comments

Restriction of oral intake for 4 to 6 hours prior to treatment may help prevent GI adverse reactions. Dacarbazine should be used with caution in patients with renal and/or liver dysfunction.

The hematologic profile should be monitored. Hematopoietic toxicity may warrant suspension or cessation of therapy. Patients should be advised to use sunscreens and to avoid sun exposure following administration of this drug.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.